Marijuana firm MedMen’s fiscal Q2 sales grow, losses shrink from previous quarter

Be at the forefront of cannabis and psychedelics science and innovation. Register by March 14 & Save $100 on tickets to The Emerald Conference by MJBiz Science, April 1-3 in San Diego.

(This story has been updated to include results from the second quarter of fiscal 2018.)

Los Angeles-based MedMen reported revenue of $29.9 million and a net loss of $64.6 million for its fiscal second quarter ended Dec. 29, as the multistate cannabis company saw its sales grow and red ink recede versus the previous quarter.

The retailer reported a net loss of $11 million on sales of $3 million for the same period a year ago.

The latest revenue figure for the newly public company – it debuted on the Canadian Securities Exchange last May – is up 39% from $21.5 million in MedMen’s first fiscal quarter ended Sept. 30, 2018.

The company’s latest net loss, meanwhile, narrowed from $66.5 million in the first quarter.

The retailer, which last week enjoyed a reprieve on closing its flagship store in West Hollywood, is a defendant in three separate lawsuits.

MedMen trades on the CSE under the ticker symbol MMEN.

More details on the fiscal second quarter results are available here.